Leinco Technologies

About Leinco Technologies

For scientists in life sciences discovery, and biopharmaceutical and diagnostics segments utilizing antibodies, biologically active proteins, and assays, reproducible science is the key to unlocking the scientific doors. Leinco Technologies Inc. adheres to ISO 9001:2015 and ISO 13485:2016 quality standards, and provides access to antibodies and proteins used in a broad range of life sciences applications uncovering interactions in cancer, infectious diseases and immunology. Our proprietary techniques result in the highest purity antibodies (monoclonal, recombinant and polyclonal) and proteins enabling scientists globally to generate reproducible science and faster time to scientific results across a broad range of cell, tissue and in vivo applications (e.g. spatial biology, flow cytometry, pre-clinical in vivo and in vitro studies). For our many partners, the Leinco scientists with over 30 years’ experience take a consultative approach and are committed to delivering the highest quality CDMO services (e.g. antibody scale-up and purification, optimized conjugation to reporter molecules and assay development/manufacturing) that save time and ensure our customers are successful in their programs.

Website	http://www.leinco.com/
Employees	11-50 employees View all Leinco Technologies employees
Industry	Biotechnology
Headquarter	410 Axminister Drive, Fenton, MO 63026, US
Founded	1992
Keywords	Antibody Production

Get verified email of Leinco Technologies employees

Leinco Technologies Alternatives

Akkord

Biotechnology

Akero Therapeutics

Biotechnology

Unchained Labs

biotechnology

ACM-Pivotal Global Central Laboratory

Biotechnology

Denali Therapeutics

biotechnology

BIOCONTROL SYSTEMS, INC.

biotechnology

CorePlus

biotechnology

Molecular Testing Labs

biotechnology

Frequently Asked Questions about Leinco Technologies

Who is the CEO of Leinco Technologies?

W Pat Leinert is the CEO of Leinco Technologies.

Who are the decision makers in Leinco Technologies?

The decision makers in Leinco Technologies are W Pat Leinert, etc. Click to Find Leinco Technologies decision makers emails.

What types of antibodies does Leinco Technologies produce?

Leinco Technologies specializes in the production of a wide range of antibodies, including monoclonal and polyclonal antibodies. These antibodies can be customized for specific applications in research, diagnostics, and therapeutics. The company offers services for both small-scale and large-scale production, ensuring that scientists have access to high-quality antibodies tailored to their specific needs.

How does Leinco ensure the quality and reproducibility of its products?

Leinco Technologies employs stringent quality control measures throughout the production process. This includes rigorous testing of raw materials, in-process controls, and final product validation. The company adheres to Good Manufacturing Practices (GMP) and provides detailed documentation, including certificates of analysis, to ensure that customers receive reproducible and reliable products for their research and development needs.

What industries does Leinco Technologies serve?

Leinco Technologies serves a variety of industries within the life sciences sector, including biopharmaceuticals, diagnostics, and academic research. The company collaborates with scientists and researchers across these fields to provide innovative solutions that support drug discovery, development, and diagnostic testing.

Can Leinco Technologies assist with custom assay development?

Yes, Leinco Technologies offers custom assay development services to meet the specific requirements of researchers. The company can develop and optimize assays using their antibodies and biologically active proteins, ensuring that the assays are tailored to the unique needs of each project. This includes ELISA, Western blotting, and other assay formats.

What is the turnaround time for antibody production at Leinco?

The turnaround time for antibody production at Leinco Technologies can vary depending on the type of antibody and the complexity of the project. Generally, monoclonal antibodies may take several months to produce, while polyclonal antibodies can be completed in a shorter timeframe. Leinco works closely with clients to establish timelines that align with their research goals.

Does Leinco Technologies provide support for regulatory submissions?

Yes, Leinco Technologies offers support for regulatory submissions, particularly for clients in the biopharmaceutical industry. The company can assist with the preparation of documentation required for regulatory compliance, including data on product quality, safety, and efficacy. This support helps clients navigate the complexities of regulatory processes and ensures that their products meet the necessary standards.